retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, an Amazing Future for Retatrutide vs. Tirzepatide for Weight

There is also a pipeline of novel drug candidates, such as small-molecule, once-a-month injectable, and dual-triple GLP-1 agonists with the GIP and glucagon receptors

When people lose weight and maintain the loss, they typically reduce their risk of obesity-related chronic illnesses, such as diabetes or heart disease

Tirzepatide (Zepbound/Mounjaro) is a dual GLP-1/GIP agonist, which explains its edge on weight loss

This test analyzes genetic variants across 14 peptide pathways, mapping 150+ personalized insights that influence how your body responds to GLP-1 therapy

Foods that make GLP-1 constipation worse Some foods actively slow transit or harden stool

But people who are on GLP-1s do eat less thats the whole point.